GlassScriptPhysician profile
Michael Tee
NPI 1508360421
$79,382.08
in general payments reported to CMS, 2019-2025
22 companies · $73K in 2025
The $73K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,340 · 2023: $2,224 · 2024: $2,057 · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Food and Beverage: $7,314 · Travel and Lodging: $2,579 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,050.00 |
| Food and Beverage | $7,313.55 |
| Travel and Lodging | $2,578.52 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $72,083.87 | 2022-2025 | Nemluvio |
| Abbvie INC. | $2,055.42 | 2022-2025 | Rinvoq, Skyrizi |
| Dermavant Sciences, INC. | $1,278.31 | 2022-2024 | Vtama |
| Genzyme Corporation | $763.04 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $556.59 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $432.52 | 2022-2025 | Ilumya, Winlevi |
| Lilly USA, LLC | $390.34 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $313.35 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $267.54 | 2022-2024 | Sotyktu |
| Verrica Pharmaceuticals INC. | $207.87 | 2024-2025 | Ycanth |
| Mayne Pharma Commercial LLC | $175.63 | 2023-2025 | |
| Ucb, INC. | $153.78 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $140.69 | 2024-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $130.23 | 2022-2024 | Jublia, Arazlo, Duobrii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.88 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Arcutis Biotherapeutics, INC. | $62.55 | 2023-2025 | Zoryve |
| Amgen INC. | $38.73 | 2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $32.66 | 2025 | |
| Leo Pharma INC. | $28.32 | 2025 | Adbry |
| Sanofi Pasteur INC. | $28.13 | 2024 | |
| Pfizer INC. | $20.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.